Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety

Certain evidence suggests that buspirone, a novel nonbenzodiazepine anxiolytic, may be a 5-HT1A serotonergic agonist and may antagonize postsynaptic dopaminergic receptors. The latter property raises questions regarding a dyskinesia- or extrapyramidal symptom-inducing potential. We monitored serum p...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical psychopharmacology Vol. 9; no. 2; p. 132
Main Authors Tollefson, G D, Godes, M, Montague-Clouse, J, Lancaster, S P, Garvey, M J
Format Journal Article
LanguageEnglish
Published United States 01.04.1989
Subjects
Adult
Anxiety - blood
Anxiety - drug therapy
Anxiety - psychology
Buspirone - adverse effects
Buspirone - blood
Buspirone - therapeutic use
Female
Growth Hormone - blood
Humans
Male
Middle Aged
Prolactin - blood
Psychiatric Status Rating Scales
Online AccessGet more information

Cover

More Information
Summary:Certain evidence suggests that buspirone, a novel nonbenzodiazepine anxiolytic, may be a 5-HT1A serotonergic agonist and may antagonize postsynaptic dopaminergic receptors. The latter property raises questions regarding a dyskinesia- or extrapyramidal symptom-inducing potential. We monitored serum prolactin and growth hormone in 10 subjects with generalized anxiety disorder and 10 matched controls before and after 4 weeks of pharmacotherapy. A drug effect upon serotonin-modulated prolactin release or on the tubero-infundibular dopamine axis (prolactin; growth hormone) was negligible at clinically effective dosages of buspirone. Concomitant buspirone levels also failed to demonstrate any significant relationships.
ISSN:0271-0749
DOI:10.1097/00004714-198904000-00012